Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,531 | -12,669 | 22,806 | -28,385 | -25,180 |
| Depreciation Amortization | 2 | N/A | 367 | 329 | 221 |
| Accounts receivable | 21,396 | 23,333 | -95,742 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,318 | 1,688 | 761 | 486 | 693 |
| Other Working Capital | 13,075 | 16,330 | -70,375 | 593 | -10,961 |
| Other Operating Activity | -18,066 | -22,744 | 109,188 | 11,475 | 3,810 |
| Operating Cash Flow | $-12,806 | $5,938 | $-32,995 | $-15,502 | $-31,417 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 221 | N/A | N/A |
| Other Financing Activity | 0 | 0 | 0 | 220 | 0 |
| Financing Cash Flow | $N/A | $N/A | $221 | $220 | $N/A |
| Beginning Cash Position | 76,333 | 76,333 | 109,107 | 109,107 | 109,107 |
| End Cash Position | 63,527 | 82,271 | 76,333 | 93,825 | 77,690 |
| Net Cash Flow | $-12,806 | $5,938 | $-32,774 | $-15,282 | $-31,417 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,806 | 5,938 | -32,995 | -15,502 | -31,417 |
| Free Cash Flow | -12,806 | 5,938 | -32,995 | -15,502 | -31,417 |